GLUE
NASDAQMonte Rosa Therapeutics Inc.
News25/Ratings11
News · 26 weeks49-33%
2025-10-262026-04-19
Mix2290d
- Insider8(36%)
- Other7(32%)
- SEC Filings6(27%)
- Offering1(5%)
Latest news
25 items- PRMonte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid TumorsCCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectivity and reduced off-target activity compared to CDK2 inhibitors Oral presentation on April 21, 2026, at 2:30 p.m. PT BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data highlighting the potential of its highly selective, first-in-class cyclin E1 (CCNE1)-directed MGD, MRT-55811, to treat CCNE1-amp
- SECSEC Form 144 filed by Monte Rosa Therapeutics Inc.144 - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
- INSIDERSEC Form 4 filed by Warmuth Markus4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERSEC Form 4 filed by Nickson Philip4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERSEC Form 4 filed by Bowen Matthew4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bowen Matthew3 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.SCHEDULE 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
- SECSEC Form S-8 filed by Monte Rosa Therapeutics Inc.S-8 - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- SECSEC Form 10-K filed by Monte Rosa Therapeutics Inc.10-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- SECMonte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- PRMonte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business UpdatesPositive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly announced unblinded safety data from MRT-8102 SAD/MAD cohorts continue to support favorable safety/tolerability profile and wide therapeutic window Company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with elevated CVD-risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim data from the Phase 1/2 clinical study of MRT-2359 in co
- PRMonte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerMRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations in an ongoing Phase 1/2 clinical study Monte Rosa plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 in combination with apalutamide targeting AR mutant patients in Q3 2026 BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced th
- INSIDERPrincipal Accounting Officer Dunn Edmund sold $2,496 worth of shares (139 units at $17.96), decreasing direct ownership by 0.61% to 22,554 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERPresident & CEO Warmuth Markus sold $97,974 worth of shares (5,466 units at $17.92), decreasing direct ownership by 0.88% to 613,471 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERPrincipal Accounting Officer Dunn Edmund exercised 25,700 shares at a strike of $13.41 and sold $464,886 worth of shares (25,700 units at $18.09) (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- INSIDERChief Medical Officer Janku Filip sold $179,161 worth of shares (9,189 units at $19.50), decreasing direct ownership by 12% to 65,837 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- PRMonte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events (AEs); no treatment discontinuations due to AEs Company plans to initiate a new, signal-confirming Phase 2 stud
- PRMonte Rosa Therapeutics to Participate in Upcoming Investor ConferencesBOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to present, March 2, 2026, at 3:10 p.m. ETBarclays 28th Annual Global Healthcare Conference (Miami, FL) – Filip Janku, M.D., Chief Medical Officer, to participate in a fireside chat, March 10, 2026, at 12:30 p.m. ET2026 Jefferies Biotech on the Beach Summit (Miami, FL) – March 11, 2026 Webcasts of the presenta
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.SCHEDULE 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.SCHEDULE 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
- SECSEC Form S-3ASR filed by Monte Rosa Therapeutics Inc.S-3ASR - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- SECSEC Form 8-K filed by Monte Rosa Therapeutics Inc.8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- SECSEC Form 8-K filed by Monte Rosa Therapeutics Inc.8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- SECSEC Form 424B5 filed by Monte Rosa Therapeutics Inc.424B5 - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.SCHEDULE 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)